Moderna Rises on Report Its Covid Shot Shows Promise in Children 6-11
By Dhirendra Tripathi
Investing.com – Moderna stock (NASDAQ:MRNA) rose 3.2% on Monday as the company said it would be approaching the Food and Drug Administration and other regulators for approval after trials of its Covid-19 vaccine in children six to 11-years-old showed promise.
The results haven’t yet been published in a peer-reviewed medical journal.
Moderna’s vaccine is currently approved for use in those aged 18 and above.
The company is a little behind Pfizer in its effort to broaden the use of its vaccines to cover children.
Pfizer (NYSE:PFE)-BioNTech's (NASDAQ:BNTX) two-dose vaccine is authorized for use in children 12 and older. The two partners could get FDA authorization in the matter of days for use of their vaccine in children aged 5-11 years.
Moderna has asked the FDA to authorize use of the vaccine in 12- to 17-year-olds but the FDA is currently probing cases of heart-inflammation in younger vaccine recipients.
Related Articles
Moderna Rises on Report Its Covid Shot Shows Promise in Children 6-11
